BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023

Product Information

The infant should be monitored for potential side-effects of drugs used by the mother during pregnancy or breast-feeding. Dose and dose frequency should be stated; in the case of preparations to be taken ‘as required’ a minimum dose interval should be specified. Where an unlicensed drug is included in the BNF, this is indicated in the unlicensed use section of the drug monograph.

an overview of the drug management or prophylaxis of common conditions intended to facilitate rapid appraisal of options (e. Dental Advisory Group The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the group includes representatives from the British Dental Association and a representative from the UK Health Departments.It is published under the authority of a Joint Formulary Committee which comprises representatives of the two professional bodies, the UK Health Departments, the Medicines and Healthcare products Regulatory Agency, and a national guideline producer. Automatic substitution of brands at the point of dispensing is not appropriate for biological medicines. Wherever appropriate the prescriber should state the current weight of the child to enable the dose prescribed to be checked. Contra-indications are far more restrictive than Cautions and mean that the drug should be avoided in a patient with a condition that is contra-indicated. Information is provided on selected excipients in skin preparations, in vaccines, and on selected preservatives and excipients in eye drops and injections.

When the BNF recommends an unlicensed medicine or the ‘off-label’ use of a licensed medicine, this is shown below the indication and dose panel in the unlicensed use section. Drug class monographs – where substantial amounts of information are common to all drugs within a drug class (e. org UK Drugs in Lactation Advisory Service (UKDILAS) Information on the compatibility of drugs with breastfeeding.For instance, in a patient who has difficulty sleeping, it may be preferable to avoid a drug that frequently causes insomnia. The more important changes are listed under Changes; changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoire for those using print copies. Liverpool: (0151) 794 8206 Driver and Vehicle Licensing Agency (DVLA) Information on the national medical guidelines of fitness to drive is available from: www.

After selecting and administering the most appropriate drug by the most appropriate route, patients should be monitored to ensure they are achieving the expected benefits from drug treatment without any unwanted sideeffects. comparing the indications, cautions, contra-indications, and side-effects with similar existing drugs. In all circumstances, it is important to consider the patient in question and their physical condition, and select the dose most appropriate for the individual.Now, all of the information for the systemic use of a drug is contained within one monograph, so codeine phosphate p. Drug monographs – where possible, all information that relates to a single drug is contained within its drug monograph, moving information previously contained in the prescribing notes. Although navigation is possible by browsing, primarily access to the information is via the index, which covers the titles of drug class monographs, drug monographs, and treatment summaries. Information on drugs is drawn from the manufacturers’ product literature, medical and pharmaceutical literature, UK health departments, regulatory authorities, and professional bodies. Anyone found to have any of the drugs (including related drugs, for example, apomorphine hydrochloride p.

There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. This section covers one-off tests required to assess the suitability of a patient for a particular drug. Nurse Prescribers’ Advisory Group The Nurse Prescribers’ Advisory Group oversees the list of drugs approved for inclusion in the Nurse Prescribers’ Formulary; the group includes representatives from a range of nursing disciplines and stakeholder organisations. Marketing authorisation and BNF advice In general the doses, indications, cautions, contra-indications, and side-effects in the BNF reflect those in the manufacturers’ data sheets or Summaries of Product Characteristics (SPCs) which, in turn, reflect those in the corresponding marketing authorisations (formerly known as Product Licences). g. asthma), followed by the monographs of the drugs used to manage the conditions discussed in the treatment summary.

Important In the absence of information on excipients or electrolytes in the BNF and in the product literature (available at www.